drugset / Trial / NCT01353027
Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus
Phase 1
Completed
30 enrolled
Sarepta Therapeutics, Inc.
United States Department of Defense · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to characterize the safety and pharmacology of single administrations of AVI-6002, a post-exposure prophylaxis candidate treatment for Ebolavirus.
Timeline
- Start
- 2010-05
- Primary completion
- 2011-11
- Completion
- 2011-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AVI-6002 | Antisense oligonucleotide | — | Intravenous |